Page 38 | Certara

Publication

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs),…

CertaraJanuary 8, 2025

Case Study

Helping Sponsor Meet EMA Policy 0070 Requirements

The European Medicines Agency’s Policy on the Publication of Clinical Data for Medicinal Products for…

CertaraJanuary 7, 2025

On-Demand Webinar

AI-powered regulatory writing software – Frequently asked questions by Japanese customers [Japanese Webinar]

Faced with more and more complex clinical research than ever before, regulatory writers are facing…

CertaraJanuary 6, 2025

On-Demand Webinar

Where to Start? Setting Your Medical Writing Team Up for Success with GenAI

Generative AI (GenAI) is poised to revolutionize writing and report generation. In fact, industry studies…

CertaraJanuary 6, 2025

On-Demand Webinar

Optimizing DDI Knowledge throughout Drug Development

Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa accumsan aliquam nibh…

CertaraJanuary 6, 2025

Press Coverage

Pharma – 2025 Health IT Predictions

Discover transformative 2025 Health IT predictions, from AI in drug discovery to personalized medicine and…

CertaraJanuary 3, 2025

On-Demand Webinar

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

SVP, Client and Regulatory Strategy, Certara Dr. Karen Rowland Yeo is Senior Vice-President, Client &…

CertaraJanuary 3, 2025

Press Release

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

January 2, 2025 RADNOR, Pa. — January 2, 2025 — Certara, Inc. (Nasdaq: CERT), a global leader…

CertaraJanuary 2, 2025

Press Coverage

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Fran Brown highlights how AI in life sciences drives more precise drug development and reduces…

CertaraDecember 24, 2024

Case Study

Streamlining the Preparation of 1-Year and 2-Year PSURs

We explore how we helped one client deliver a last-minute addition to a Periodic Safety…

CertaraDecember 18, 2024

INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease

Helping Sponsor Meet EMA Policy 0070 Requirements

AI-powered regulatory writing software – Frequently asked questions by Japanese customers [Japanese Webinar]

Where to Start? Setting Your Medical Writing Team Up for Success with GenAI

Optimizing DDI Knowledge throughout Drug Development

Pharma – 2025 Health IT Predictions

From Research to Real-World Impact: A Model Informed Drug Development (MIDD) Framework to Support Understudied Populations

Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AI in Life Sciences Finds an Early Success and Will Continue in 2025

Streamlining the Preparation of 1-Year and 2-Year PSURs

Newsletter sign up

Quick links

Solutions

Contact